Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Teladoc Health sells virtual doctor visits and remote health monitoring, letting people see a doctor or therapist by phone or video instead of going to a clinic.
Teladoc Health is a virtual care company. It lets you talk to a doctor, therapist, or specialist through an app or phone call instead of sitting in a waiting room. Your health insurer or your employer usually pays for it, and in exchange their members get quick access to care — often the same day — without driving anywhere.
The business has two main parts. One is general medical care: a sore throat, a rash, a prescription refill, a quick check-in with a therapist. The other, which Teladoc bought its way into, is chronic condition management — remote monitoring for things like diabetes, high blood pressure, and heart issues, where devices and coaches keep an eye on patients between visits. Insurers and big employers like this because a cheap video visit can replace an expensive emergency room trip, and keeping a diabetic patient healthy saves money down the road. Here is the hard truth about the business: it has struggled. Teladoc became a pandemic-era stock market darling as locked-down patients flocked to video visits, then demand cooled as people returned to normal life. Its huge bet on remote monitoring — the 2020 purchase of Livongo for $18.5 billion — turned into one of the most infamous write-downs in recent memory, with the company eventually taking billions in impairment charges on that deal. Revenue growth has stalled, and the company has reported net losses in recent years while trying to convince investors the long-term story still works.
In 2002, two founders in Dallas, Texas, had a simple idea: why should you have to sit in a waiting room to see a doctor? They built a service that let patients talk to a licensed doctor by phone at any time. Companies paid a monthly fee so their employees could use it, and patients paid a flat fee of around thirty-five dollars per visit. That was the start of what became the oldest and largest telemedicine company in the United States.
A few years later, the startup launched across the country at a health care conference in Chicago. The timing was good. Large employers like AT&T began offering Teladoc to their workers as a health benefit, which meant the company no longer had to sell one patient at a time.
By 2015, the company was ready for the public markets, and it listed on the New York Stock Exchange as the only telemedicine company there. Shares were priced at nineteen dollars, and on the first day they jumped fifty percent. Investors were betting that visiting a doctor would one day be as easy as opening an app.
That same year, Teladoc made a small bet that would matter far more than anyone expected. It bought Compile Inc., which ran a service called BetterHelp, for a few million dollars. The idea was to offer therapy online. Over time, BetterHelp grew into Teladoc's direct-to-consumer mental health business, and one of its two main reporting segments.
In 2017, Teladoc made its biggest purchase yet, paying about four hundred forty million dollars for Best Doctors, a firm that helps patients get a second opinion on serious medical questions. Sales that year nearly doubled from the year before. The company was no longer just a phone line to a doctor; it was adding deeper medical expertise.
The following year, the company changed its name from Teladoc, Inc. to Teladoc Health, Inc. It kept the same stock listing, but the new name said something important: this was no longer only about telemedicine. The company wanted to be a broader health brand.
Then came the biggest bet of all. In 2020, Teladoc bought Livongo Health, a company that helps people manage chronic conditions like diabetes with remote monitoring, for nearly fourteen billion dollars. It was one of the largest deals for a U.S. company that year, and the combined business was valued at around thirty-seven billion dollars. The logic was to pair quick virtual visits with ongoing care for long-term illnesses.
For a moment, it looked like a brilliant move. With doctor offices shut during the pandemic, telemedicine exploded, and Teladoc shares topped three hundred dollars in early 2021. Then the world reopened, competition grew, and interest in virtual care cooled. The stock fell more than ninety percent from its peak, and that crash became the backdrop for everything that followed.
The long slide finally reached the top of the company. In April 2024, CEO Jason Gorevic, who had led Teladoc since 2009, left immediately. The chief financial officer stepped in while the board searched for a replacement. The company had lost about two hundred twenty million dollars the year before, and the stock was down more than ninety percent from its high, so the board wanted a new direction.
Two months later, Teladoc named Chuck Divita as its new chief executive. He set out to steady the ship: cut costs, simplify the business, and invest where growth was real. One early move was a program called Wellbound, which folded BetterHelp into the mental health benefits that U.S. employers offer their workers.
In 2025, the company made two smaller, targeted deals. It bought Catapult Health, which sends nurses to people's homes to draw blood, so Teladoc can spot health problems early and steer patients into its other services. It also bought a mental health provider called UpLift, which gave BetterHelp a path into insurance coverage. Both deals were about connecting the pieces rather than getting bigger for its own sake.
Not every problem was about strategy. In March 2025, the Federal Trade Commission fined BetterHelp nearly eight million dollars for sharing user data with social media sites, and banned the company from sharing health data for advertising. A new investor lawsuit followed. The fine was a reminder that BetterHelp, the company's biggest growth engine, also carried real legal and regulatory risk.
By 2026, Teladoc was ready to show what all the pieces were for. It announced Teladoc One, a new model of virtual care built around the whole person instead of one disease at a time. It pairs teams of different specialists with always-on AI support, and uses a system called Pulse to spot needs earlier and coordinate care. The service drew on more than a hundred million visits and was set to reach the broad market in 2027.
The early results gave the new team something to point to. In the third quarter of 2026, Teladoc beat its profit guidance and shares rose eleven percent, helped by BetterHelp insurance revenue jumping to about thirty-two million dollars. The company is shifting BetterHelp from cash payments toward insurance coverage, which should lower the cost of finding customers and help them stay in therapy. But revenue still fell three percent, and nearly a billion dollars of debt is due within a year, so cash flow is still the real test.
So what is the actual pitch? Teladoc's argument is that virtual care is not a fad but a permanent shift, and that its scale — tens of millions of paid members — plus its data and chronic-care tools make it the default partner for insurers and employers. Its competitors include other telehealth providers and traditional clinic chains, but the bigger threat may be that the major health insurers and hospital systems build their own virtual care instead of paying a middleman. The company has also been pushing international expansion and deeper integration with chronic care, hoping those stickier, recurring relationships replace the one-off sniffle visits that made it famous.
Saved answer · last researched 30 Oct 2026